Apnimed, Inc.

APMD

NASDAQHealthcareBiotechnology

公司概況

Apnimed, Inc. operates as a clinical pharmaceutical company that develops and manufactures novel oral therapies that address the neurobiology of sleep-related breathing diseases in global markets. Its products include AD109, an oral therapy designed to treat obstructive sleep apnea (OSA) by targeting the underlying neuromuscular dysfunction. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.

產業: Biotechnology
部門: Healthcare
總部: US
執行長: Kevin R. Lind
上市以來: 2026年7月29日
僱員: 65

市場位置

成交量: 8.72萬; 0.17× 平均值
平均成交量: 51.66萬; 日均成交量
市值: 10.44億 USD
貝塔: 0; 市場參考 1

APMD 訊息

247wallst.com2026年8月14日

Apnimed's Nasdaq Debut Bets Big on a Pill to Dethrone CPAP Masks

The Nasdaq debut of Apnimed (NASDAQ:APMD) has given public investors their first pure-play bet on a pill for obstructive sleep apnea (OSA).

閱讀原始碼

globenewswire.com2026年8月3日

Apnimed Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

CAMBRIDGE, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Apnimed, Inc. (Nasdaq: APMD) (“Apnimed”), a late stage clinical pharmaceutical company dedicated to the discovery, development and commercialization of novel oral…

閱讀原始碼

reuters.com2026年7月27日

Sleep apnea pill developer Apnimed targets $608 million valuation in US IPO

Late-stage drug developer Apnimed is targeting a valuation of up to $608 million in its initial public offering in the United States.

閱讀原始碼

seekingalpha.com2026年7月23日

Apnimed Seeks IPO For OSA Treatment Commercialization

Apnimed, Inc. is pursuing an IPO to fund regulatory approval and initial commercialization of its lead OSA drug, Oxnimbi (AD109). AD109 has shown strong efficacy in Phase 3 trials and an FDA decision is expected within a…

閱讀原始碼